Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK cells plus chemotherapy in treatment-naive stage IV EGFR-wild-type lung adenocarcinoma
ChiCTR-IPR-15007015Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2015
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous cytokine-induced killer cells in Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Overall survival. Planned start Oct 2015; status: not yet recruiting.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-15007015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007015.